The must-pass bill will include provisions related to generic drug competition and biologic drug competition.

Sure, the House passed it. Going from that to monster retirement plan sales could still be hard.

Cigna would get cash. New York Life would get a buffer against low interest rates.

Some state exchange programs have also adjusted their signup deadlines.

The U.S. Government Accountability Office looked at the state of MHPAEA compliance--here's what it found.

Even if H.R. 3 doesn't pass, members of Congress could move popular some of its provisions into a must-pass spending bill.

The nature of the worst-hit class of medical bill victims might surprise you...

The Health Insurance & Long Term Care Issues Committee has given outsiders a peek into the evolution of short-term health insurance coverage.